Literature DB >> 25230158

Thymosin beta 4 improves dermal burn wound healing via downregulation of receptor of advanced glycation end products in db/db mice.

Sokho Kim1, Jungkee Kwon2.   

Abstract

BACKGROUND: The delay of dermal burn wound healing caused by vascular disorders is a critical problem for many diabetic patients. Thymosin β4 (Tβ4), identified by subtractive cloning of endothelial cells on plastic versus basement membrane substrates, has been found to promote angiogenesis and dermal wound repair in rats, aged mice, and db/db diabetic mice. However, previous studies involving the role of Tβ4 in wound repair were limited to mechanical damage and dermal impairment. Thus, this study aimed to evaluate the improvement of healing of burn wounds by Tβ4 in relation to advanced glycation end products (AGE), which are pathological factors in diabetes.
METHODS: We adapted a dermal burn wound in vivo model in which the dorsal skin of db/db mice was exposed for 10s to 100°C heated water to produce a deep second-degree burn 10mm in diameter. Five mg/kg of Tβ4 was then injected intradermally near the burn wound twice a week for 2weeks.
RESULTS: After treatment, Tβ4 improved wound healing markers such as wound closure, granulation, and vascularization. Interestingly, Tβ4 reduced levels of receptor of AGE (RAGE) during the wound healing period.
CONCLUSIONS: Tβ4 exerts effects to remedy burn wounds via downregulation of RAGE. GENERAL SIGNIFICANCE: Our results suggest the potential importance of Tβ4 as a new therapy for impaired burn wound healing that is associated with diabetes.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Burn wound; Diabetes; RAGE; Thymosin β4; Vascularization

Year:  2014        PMID: 25230158     DOI: 10.1016/j.bbagen.2014.09.013

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Actin cytoskeletal rearrangement and dysfunction due to activation of the receptor for advanced glycation end products is inhibited by thymosin beta 4.

Authors:  Sokho Kim; Jungkee Kwon
Journal:  J Physiol       Date:  2015-02-27       Impact factor: 5.182

2.  A novel sprayable thermosensitive hydrogel coupled with zinc modified metformin promotes the healing of skin wound.

Authors:  Zhengwei Liu; Wanze Tang; Jiayi Liu; Yingying Han; Qinnan Yan; Yuechao Dong; Xiaomei Liu; Dazhi Yang; Guixing Ma; Huiling Cao
Journal:  Bioact Mater       Date:  2022-07-01

3.  Glu-Trp-ONa or its acylated analogue (R-Glu-Trp-ONa) administration enhances the wound healing in the model of chronic skin wounds in rabbits.

Authors:  Maxim A Shevtsov; Larisa V Smagina; Tatiana A Kudriavtceva; Sergey V Petlenko; Irina V Voronkina
Journal:  Drug Des Devel Ther       Date:  2015-03-20       Impact factor: 4.162

4.  Roles of p300 and cyclic adenosine monophosphate response element binding protein in high glucose-induced hypoxia-inducible factor 1α inactivation under hypoxic conditions.

Authors:  Lingtao Ding; Minlie Yang; Tianlan Zhao; Guozhong Lv
Journal:  J Diabetes Investig       Date:  2017-01-24       Impact factor: 4.232

Review 5.  The effects of advanced glycation end products (AGEs) on dermal wound healing and scar formation: a systematic review.

Authors:  Lennert Van Putte; Sofie De Schrijver; Peter Moortgat
Journal:  Scars Burn Heal       Date:  2016-12-05

6.  Effects of Thymosin β4 on Myocardial Apoptosis in Burned Rats.

Authors:  Xiaoming Wu; Shusong Li; Xinshu Feng; Hailing Wen; Xiangxi Meng; Kui Sun
Journal:  J Healthc Eng       Date:  2022-03-03       Impact factor: 2.682

7.  Thymosin Beta-4 and Ciprofloxacin Adjunctive Therapy Improves Pseudomonas aeruginosa-Induced Keratitis.

Authors:  Thomas W Carion; Abdul Shukkur Ebrahim; David Kracht; Aditya Agrawal; Eliisa Strand; Omar Kaddurah; Cody R McWhirter; Gabriel Sosne; Elizabeth A Berger
Journal:  Cells       Date:  2018-09-20       Impact factor: 6.600

8.  Effects of thymosin β4 on neuronal apoptosis in a rat model of cerebral ischemia‑reperfusion injury.

Authors:  Zhongsheng Zhang; Shuangfeng Liu; Sichun Huang
Journal:  Mol Med Rep       Date:  2019-09-13       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.